|
Fast Facts About Genzyme Corporation
Founded:
|
1981
|
2010 Revenues:
|
$4.05 billion
|
2010 R&D Spending:
|
$786 million
|
Employees Worldwide:
|
Approximately 10,000
|
Headquarters:
|
Cambridge, MA
|
Areas of Focus:
|
Rare Genetic Diseases, Multiple Sclerosis, Cardiovascular Disease, Endocrinology
|
Parent Company:
|
In 2011, Genzyme became a Sanofi company.
|
|
|
|
Top Products, based on FY 2010 Revenue:
|
Product Name
|
Disease/Condition
|
Revenue 2010
|
Cerezyme® (imiglucerase for injection)
|
Gaucher disease
|
$720 million
|
Sevelamer (Renagel® and Renvela®)
|
renal disease
|
$698 million
|
Alglucosidase alfa (Myozyme® and Lumizyme®)
|
Pompe disease
|
$412 million
|
Synvisc® (hylan G-F 20)
|
osteoarthritis of the knee
|
$393 million
|
|
|
Key Pipeline Products:
|
Product Name
|
Disease/Condition
|
alemtuzumab
|
multiple sclerosis
|
mipomersen
|
familial hypercholesterolemia
|
eliglustat tartrate
|
Gaucher disease type 1
|
International Presence:
|
Genzyme has nearly 65 locations in over 40 countries, including 11 manufacturing facilities; the company's products are available in nearly 100 countries.
|
Charitable Contributions, FY 2010:
|
Global product donations, $75 million
|
U.S. cash contributions, $12 million
|
|
Home
